U.S., Jan. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07365839) titled 'Cemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular Carcinoma' on Jan. 16.
Brief Summary: Randomized, 2-arm, non-comparative, pilot study assessing the efficacy of cemiplimab with or without fianlimab after treatment with yttrium-90 (Y90).
Study Start Date: Feb. 01
Study Type: INTERVENTIONAL
Condition:
Hepatocellular Carcinoma
Intervention:
DRUG: Arm 1 cemiplimab
Cemiplimab 350mg IV every 3 weeks up to 1 year.
DRUG: Arm 2 cemiplimab and fianlimab
Cemiplimab 350mg IV and fianlimab 1600mg every 3 weeks up to 1 year
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Virginia Commonwealth Universi...